That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
Approval status may also vary by country and over time, so patients should rely on up-to-date medical advice rather than assumptions
Finally, for the primary endpoint MACE, both SGLT-2 inhibitors and GLP-1RA are similar and both are superior to DPP-4 inhibitors
Knowing when to seek medical evaluation prevents dismissing something that needs attention
Lets move on to explore the alternatives
Complete an online intake form